Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055783 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00055783: Completed Phase 2 study, sponsored by Stanford University.
NCT00055783 is a Phase 2 study that has completed, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055783, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have progressive or recurrent Hodgkin's lymphoma.
Interventions
- BIOLOGICAL apolizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-07 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055783
The ClinicalTrials.gov registry entry for NCT00055783 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apolizumab is the first listed.
NCT00055783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055783 about?
NCT00055783 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have progressive or recurrent Hodgkin's...
What is the current status of trial NCT00055783?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-07. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00055783?
The interventions under investigation include: apolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055783?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.